Current screening or monitoring tests of cancer progression, such as prostate-specific antigen (PSA; prostate), CA-125 (ovarian), alpha fetoprotein (liver), or CA19-9 (pancreatic) often lack the sensitivity or specificity to provide highly accurate clinical diagnoses [18–20]. This evidence concerns the gene KLK3 and cancer.